US Patent

US8609863 — Bendamustine pharmaceutical compositions

Formulation · Assigned to Cephalon LLC · Expires 2026-01-12 · 0y expired

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use.

USPTO Abstract

The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Drugs covered by this patent

bendamustine-hydrochloride (BENDAMUSTINE HYDROCHLORIDE)

Patent Metadata

Patent number: US8609863
Jurisdiction: US
Classification: Formulation
Expires: 2026-01-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Cephalon LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.